Facebook Live – Algernon Pharmaceuticals Update with CEO Christopher Moreau
Ifenprodil COVID-19 Updates with Algernon CEO Christopher Moreau
The Science behind Ifenprodil and COVID -19
Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient
Algernon Pharmaceuticals has big upside, says Mackie Research
‘An effective treatment to reduce the severity and duration of a COVID infection’ – The Mercury
Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial
Miami Herald – A pill that may lessen COVID-related lung damage. Miami will be the first in U.S. to test it.
Algernon Pharmaceuticals studies on Ifenprodil begins with patients on two fronts
Algernon’s Ifenprodil COVID-19 Trials in Florida Reported in The Guardian’s U.S. Edition
Algernon Pharmaceuticals announces first site for U.S. clinical trial for Ifenprodil
Algernon Pharmaceuticals Begins Screening Patients for Phase 2 Chronic Cough and IPF Study
Equity Guru – Algernon gets ethical green light for human trials for COVID-19 fighter Ifenprodil
Algernon Pharmaceuticals receives ethics approval as the company begins clinical trials for Ifenprodil
Human trials approved for B.C. drug company to treat COVID-19
Algernon Pharmaceuticals Receives U.S. FDA Clearance for Phase 2b/3 Ifenprodil Human Study
Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD
Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19
Algernon Pharmaceuticals applies for Phase 2b/3 study on Ifenprodil in Australia – Interview
Algeron Pharmaceuticals in the spotlight with lead drug Ifenprodil as promising coronavirus therapy
As Pandemic Progresses, Promising Projects Thrive or Fail in Rally for Effective Coronavirus Treatment
Algernon Pharmaceuticals receives OK from South Korea for phase two study of Ifenprodil
Algernon Pharmaceuticals receives positive feedback from Health Canada for NP-120 (Ifenprodil)
Algernon Pharmaceuticals updates Phase 2 human testing of NP-120 (Ifenprodil) for COVID-19
Equity Insight – Interview with CEO of Algernon Pharmaceuticals
WEBCAST: Presents: Algernon Pharmaceuticals (CSE: AGN   OTCQB: AGNPF)
Whistler Capital Event Conference
FierceBiotech: Algernon signs Novotech up for midstage respiratory therapy test
Proactive Investors: Algernon Pharmaceuticals finding new uses for safe, older drugs
Pulmonary Fibrosis News: Repurposed Anti-fibrotic Medication, NP-120, Set for Phase 2 Testing for IPF
The Georgia Straight: Vancouver company repurposes Soviet Union doping drug to cure kidney disease
Stockhouse: Taking Unparalleled Results to Treat the Next Epidemic
Share via
Copy link
Powered by Social Snap